Drug or treatment

Tarlatamab clinical trials

• 19Clinical trials
• 17Countries

Newest trials

All recruiting trials (19)

• Tarlatamab in strong-performance-status small-cell lung cancer

  This trial tests whether tarlatamab can help people with extensive-stage small-cell lung cancer and poor health (ECOG 2) who have already had prior treatment.

  Recruiting at 8 sites Phase 2 AIO-Studien-gGmbH · Berlin and 7 other locations · NCT07803848

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

• Tarlatamab plus ZL-1310, with or without durvalumab, for small cell lung cancer

  This trial will test whether combining tarlatamab with ZL-1310, with or without the PD-L1 drug durvalumab, is safe and tolerable for adults with small cell lung cancer who have received platinum chemotherapy or are newly diagnosed extensive-stage after one cycle of chemo.

  Recruiting at 27 sites Phase 1 Amgen · Goodyear, Arizona and 26 other locations · NCT07531095

• Tarlatamab treatment for extensive-stage small cell lung cancer

  This phase II trial tests tarlatamab, a bispecific antibody, to see if it helps adults with extensive-stage small cell lung cancer live longer and delay tumor growth.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07423585

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• Tarlatamab plus temozolomide for DLL3-positive high-grade brain and other CNS tumors

  This trial tests whether adding the experimental immunotherapy tarlatamab to a fixed, low-dose temozolomide schedule helps adolescents and adults (≥12 years) with DLL3-positive recurrent or refractory high-grade brain and other CNS tumors.

  Recruiting at 8 sites Phase 1/2 Centre Leon Berard · Angers and 11 other locations · NCT07243470

• Tarlatamab as maintenance treatment after chemo-radiotherapy for limited-stage small-cell lung cancer.

  This trial will test whether giving tarlatamab after chemo-radiotherapy helps people with limited-stage small-cell lung cancer stay progression-free longer.

  Recruiting at 20 sites Phase 2 Fundación GECP · Albacete, Albacete and 19 other locations · NCT07242547

• Tarlatamab for previously treated extensive-stage small cell lung cancer with ECOG performance status 2

  This trial tests whether tarlatamab can help people with extensive-stage small cell lung cancer who progressed after one platinum‑etoposide plus immune checkpoint inhibitor regimen and have an ECOG performance status of 2.

  Recruiting at 11 sites Phase 2 ETOP IBCSG Partners Foundation · Angers and 18 other locations · NCT07203053

• Tarlatamab for DLL3-positive metastatic prostate cancer

  This study will try tarlatamab in adults with metastatic, DLL3-positive prostate cancer that has relapsed or not responded to previous treatments.

  Recruiting at 10 sites Phase 2 Memorial Sloan Kettering Cancer Center · San Diego, California and 9 other locations · NCT07111507

• Tarlatamab plus AB248 for extensive-stage small cell lung cancer (DeLLphi-311)

  This trial tests whether combining tarlatamab with AB248 is safe and tolerable for adults whose extensive-stage small cell lung cancer has progressed after prior therapy.

  Recruiting at 18 sites Phase 1 Amgen · Gilbert, Arizona and 18 other locations · NCT07037758

• Tarlatamab for advanced small‑cell lung cancer and other high‑grade neuroendocrine cancers

  This study tests whether tarlatamab can help people with advanced small‑cell lung cancer or other high‑grade neuroendocrine cancers that express DLL3.

  Recruiting at 3 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Bordeaux and 2 other locations · NCT07016230

• Hospital-at-Home program for patients receiving Tarlatamab

  This study is testing if a Hospital-at-Home program can help adults with advanced small cell lung cancer who are getting tarlatamab feel better while being monitored from home instead of staying in the hospital.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06957314

• Tarlatamab versus standard chemotherapy for pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas

  This trial tests whether tarlatamab helps adults with DLL3-positive, pre-treated advanced pulmonary (large-cell) or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas compared with standard chemotherapy.

  Recruiting at 40 sites Phase 3 Intergroupe Francophone de Cancerologie Thoracique · Angers and 39 other locations · NCT06937905

• Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma

  This study will test tarlatamab to see if it can shrink tumors and control disease in adults with relapsed extrapulmonary neuroendocrine carcinoma after prior platinum-based chemotherapy.

  Recruiting at 2 sites Phase 2 Asan Medical Center · Seoul and 3 other locations · NCT06893783

• Tarlatamab with carboplatin/etoposide and atezolizumab for EGFR‑mutant lung adenocarcinoma that changed into small cell lung cancer

  This trial tests whether adding tarlatamab to standard platinum‑etoposide chemotherapy and atezolizumab helps patients whose EGFR‑mutant lung adenocarcinoma has transformed into small cell lung cancer.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gangnam-gu · NCT06830694

• Tarlatamab for advanced EPSCC and NEC

  This study tests tarlatamab in adults with advanced extrapulmonary small cell carcinoma or neuroendocrine carcinoma who have already had platinum-based chemotherapy fail.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei, Please Select · NCT06816394

• Radiation plus tarlatamab for DLL3-expressing tumors

  This trial will test whether giving tarlatamab together with standard palliative or consolidative radiation is safe for adults with DLL3-expressing or DLL3-prevalent tumors such as melanoma, medullary thyroid cancer, sinonasal undifferentiated carcinoma, esthesioneuroblastoma, and bladder cancer.

  Recruiting at 3 sites Phase 1/2 University of Arizona · Gilbert, Arizona and 2 other locations · NCT06814496

• Tarlatamab for recurrent IDH‑mutant astrocytoma and oligodendroglioma

  This trial will try tarlatamab, an immune‑engaging drug, in adults with recurrent or refractory IDH‑mutant astrocytoma or oligodendroglioma to see if it shrinks tumors or slows progression.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT06776250

• Tarlatamab treatment for extensive stage small cell lung cancer

  This study is testing a new treatment called tarlatamab for people with extensive stage small cell lung cancer who haven't had success with previous chemotherapy to see if it helps them feel better.

  Recruiting at 31 sites Phase 1 Amgen · Los Angeles, California and 30 other locations · NCT06598306

Quick answers

How many clinical trials of Tarlatamab are recruiting right now?

19, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 17 countries. The most sites are in United States (8 trials), France (5 trials), Spain (4 trials), Switzerland (4 trials), South Korea (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 1: 3, Phase 1/2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →